Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Deals
  5. Alliances Collaborations Licensing
  6. Product Acquisitiondisposal

Product Acquisition/Disposal

Evaluate

February 22, 2023

US deal watchdog's bark could be worse than its bite

Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?  

Thumbnail
December 13, 2022

Takeda Tyks the deal-making box

For $4bn up front, Takeda buys into the Tyk2 mechanism – and Nimbus and its backers get a huge pay day.

Article image
Vantage logo
June 03, 2022

Turning Point and Libtayo steal some pre-Asco thunder

On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.

Article image
Vantage logo
July 13, 2021

Novo bets against Crispr for amyloidosis

Novo moves into amyloidosis not long after Intellia made a splash here.

Article image
Vantage logo
May 26, 2020

Merck joins Covid-19 pack with vaccine and antiviral deals

Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.

Article image
Vantage logo
December 09, 2019

J&J bets $750m that bermekimab has the X factor

Article image
Vantage logo
October 21, 2019

Bavarian’s chance to draw a line under oncology

The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.

Article image
Vantage logo
October 15, 2019

Admedus moves from one unlikely area to another

A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.

Article image
Vantage logo
August 19, 2019

Celgene's myelofibrosis win represents an expensive green light

Article image
Vantage logo
December 19, 2018

Apollo and Reshape play pass the parcel

Article image
Vantage logo
December 17, 2018

Lilly buys into ion channels – again

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up